NASDAQ:ATNX - Athenex Stock Price Target and Predictions

  • Consensus Rating: Hold
  • Consensus Price Target: $7.00
  • Forecasted Upside: 560.38 %
  • Number of Analysts: 8
  • Breakdown:
  • 0 Sell Ratings
  • 5 Hold Ratings
  • 3 Buy Ratings
  • 0 Strong Buy Ratings
$1.06
▼ -0.03 (-2.75%)

This chart shows the closing price for ATNX by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New Athenex Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for ATNX and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for ATNX

Analyst Price Target is $7.00
▲ +560.38% Upside Potential
This price target is based on 8 analysts offering 12 month price targets for Athenex in the last 3 months. The average price target is $7.00, with a high forecast of $13.00 and a low forecast of $4.00. The average price target represents a 560.38% upside from the last price of $1.06.

This chart shows the closing price for ATNX for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart

Current Consensus is Hold

The current consensus among 8 polled investment analysts is to hold stock in Athenex. This rating has held steady since September 2020, when it changed from a Buy consensus rating.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 2 buy ratings
  • 2 hold ratings
  • 0 sell ratings
7/29/2020
  • 0 strong buy ratings
  • 2 buy ratings
  • 3 hold ratings
  • 0 sell ratings
10/27/2020
  • 0 strong buy ratings
  • 1 buy ratings
  • 3 hold ratings
  • 0 sell ratings
1/25/2021
  • 0 strong buy ratings
  • 3 buy ratings
  • 5 hold ratings
  • 0 sell ratings
4/25/2021
  • 0 strong buy ratings
  • 3 buy ratings
  • 5 hold ratings
  • 0 sell ratings
7/24/2021
  • 0 strong buy ratings
  • 3 buy ratings
  • 5 hold ratings
  • 0 sell ratings
10/22/2021
  • 0 strong buy ratings
  • 3 buy ratings
  • 5 hold ratings
  • 0 sell ratings
12/21/2021
  • 0 strong buy ratings
  • 3 buy ratings
  • 5 hold ratings
  • 0 sell ratings
1/20/2022

Latest Recommendations

  • 0 strong buy ratings
  • 3 buy ratings
  • 5 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
10/12/2021Royal Bank of CanadaLower Price TargetOutperform$8.00 ➝ $5.00High
8/6/2021Royal Bank of CanadaLower Price TargetOutperform$9.00 ➝ $8.00Medium
8/6/2021SVB LeerinkLower Price TargetMarket Perform$5.00 ➝ $4.00High
7/8/2021SVB LeerinkReiterated RatingHoldHigh
7/6/2021OppenheimerReiterated RatingHoldHigh
7/6/2021Needham & Company LLCReiterated RatingHoldHigh
5/9/2021SVB LeerinkReiterated RatingHoldLow
3/9/2021Truist FinancialReiterated RatingBuy ➝ Hold$29.00 ➝ $6.00Low
3/8/2021SVB LeerinkReiterated RatingOutperform ➝ Market Perform$22.00 ➝ $5.00N/A
3/8/2021JPMorgan Chase & Co.Reiterated RatingOverweight ➝ Neutral$30.00 ➝ $7.00N/A
3/8/2021OppenheimerReiterated RatingOutperform ➝ Market PerformN/A
3/2/2021Royal Bank of CanadaBoost Price TargetPositive ➝ Outperform$9.00 ➝ $33.00Medium
3/2/2021OppenheimerDowngradeOutperform ➝ Market PerformMedium
3/2/2021Truist FinancialDowngradeBuy ➝ Hold$6.00Medium
3/1/2021SVB LeerinkDowngradeOutperform ➝ Market Perform$22.00 ➝ $5.00High
3/1/2021JPMorgan Chase & Co.DowngradeOverweight ➝ Neutral$30.00 ➝ $7.00High
3/1/2021LaidlawLower Price TargetBuy$38.00 ➝ $13.00Medium
3/1/2021Needham & Company LLCDowngradeBuy ➝ HoldLow
2/10/2021Evercore ISIInitiated CoverageOutperformLow
11/5/2020Needham & Company LLCLower Price TargetBuy$30.00 ➝ $27.00Medium
10/26/2020SVB LeerinkInitiated CoverageOutperform$22.00Low
9/1/2020Royal Bank of CanadaBoost Price TargetOutperform$31.00 ➝ $33.00Low
6/22/2020Needham & Company LLCReiterated RatingBuy$30.00Medium
6/7/2020OppenheimerInitiated CoverageBuy$23.00High
5/13/2020OppenheimerReiterated RatingBuy$23.00Medium
5/7/2020OppenheimerReiterated RatingBuy$23.00Low
4/9/2020Needham & Company LLCReiterated RatingBuy$30.00N/A
12/16/2019Needham & Company LLCReiterated RatingBuy$30.00High
12/6/2019SunTrust BanksInitiated CoverageBuy$28.00High
11/19/2019Royal Bank of CanadaReiterated RatingBuy$31.00Medium
7/30/2019SunTrust BanksBoost Price TargetBuy$30.00Low
6/25/2019Royal Bank of CanadaReiterated RatingOutperform ➝ Outperform$29.00 ➝ $31.00Low
5/2/2019CIBCInitiated CoverageOutperform ➝ Outperform$20.00Medium
5/2/2019OppenheimerInitiated CoverageOutperform$20.00High
3/29/2019SunTrust BanksInitiated CoverageBuy ➝ Buy$20.00Medium
3/12/2019Royal Bank of CanadaReiterated RatingOutperformMedium
11/15/2018JPMorgan Chase & Co.UpgradeNeutral ➝ Overweight$24.00 ➝ $15.00High
10/25/2018LADENBURG THALM/SH SHInitiated CoverageBuy$27.00High
3/6/2018Needham & Company LLCInitiated CoverageBuy ➝ Buy$30.00High
1/24/2018JPMorgan Chase & Co.Boost Price TargetNeutral ➝ Neutral$22.20 ➝ $23.00Low
1/17/2018Deutsche Bank AktiengesellschaftSet Price TargetBuy$20.00High
10/18/2017JPMorgan Chase & Co.Initiated CoverageNeutral ➝ Neutral$22.20N/A
9/19/2017LaidlawInitiated CoverageBuy$36.00Medium
9/18/2017Credit Suisse GroupInitiated CoverageOutperform ➝ Outperform$25.00Low
9/14/2017Royal Bank of CanadaInitiated CoverageOutperform ➝ Outperform$35.00High
7/10/2017Deutsche Bank AktiengesellschaftInitiated CoverageBuy$20.00Low
(Data available from 1/20/2017 forward)

News Sentiment Rating

0.39 (Hold)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
6/24/2021
  • 2 very positive mentions
  • 6 positive mentions
  • 2 negative mentions
  • 1 very negative mentions
7/24/2021
  • 3 very positive mentions
  • 13 positive mentions
  • 2 negative mentions
  • 0 very negative mentions
8/23/2021
  • 3 very positive mentions
  • 6 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
9/22/2021
  • 1 very positive mentions
  • 15 positive mentions
  • 4 negative mentions
  • 3 very negative mentions
10/22/2021
  • 0 very positive mentions
  • 15 positive mentions
  • 4 negative mentions
  • 3 very negative mentions
11/21/2021
  • 0 very positive mentions
  • 6 positive mentions
  • 2 negative mentions
  • 3 very negative mentions
12/21/2021
  • 1 very positive mentions
  • 8 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
1/20/2022

Current Sentiment

  • 1 very positive mentions
  • 8 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Athenex logo
Athenex, Inc. is a biopharmaceutical company, which engages in the discovery, development and commercialization of novel therapies for the treatment of cancer. It operates through the following segments: Oncology Innovation Platform, Global Supply Chain Platform, and Commercial Platform. The Oncology Innovation Platform segment focuses on the research and development of proprietary drugs. The Global Supply Chain Platform segment provides supply of active pharmaceutical ingredients (APIs) for clinical and commercial efforts. The Commercial Platform segment involves the sale and marketing of specialty drugs and market development of proprietary drugs. The company was founded by Lyn M. Dyster and David G. Hangauer in November 2003 and is headquartered in Buffalo, NY.
Read More

Today's Range

Now: $1.06
Low: $1.06
High: $1.15

50 Day Range

MA: $1.55
Low: $1.06
High: $2.10

52 Week Range

Now: $1.06
Low: $1.03
High: $15.00

Volume

672,676 shs

Average Volume

984,229 shs

Market Capitalization

$115.88 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.58

Frequently Asked Questions

What sell-side analysts currently cover shares of Athenex?

The following Wall Street analysts have issued reports on Athenex in the last year: Evercore ISI, JPMorgan Chase & Co., Laidlaw, Needham & Company LLC, Oppenheimer Holdings Inc., Royal Bank of Canada, SVB Leerink LLC, Truist Financial Co., and Zacks Investment Research.
View the latest analyst ratings for ATNX.

What is the current price target for Athenex?

5 Wall Street analysts have set twelve-month price targets for Athenex in the last year. Their average twelve-month price target is $7.00, suggesting a possible upside of 560.4%. Laidlaw has the highest price target set, predicting ATNX will reach $13.00 in the next twelve months. SVB Leerink LLC has the lowest price target set, forecasting a price of $4.00 for Athenex in the next year.
View the latest price targets for ATNX.

What is the current consensus analyst rating for Athenex?

Athenex currently has 5 hold ratings and 3 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Hold." A "hold" rating indicates that analysts believe investors should keep any existing positions they have in ATNX, but not buy more shares or sell existing shares.
View the latest ratings for ATNX.

How do I contact Athenex's investor relations team?

Athenex's physical mailing address is 1001 Main Street Suite 600, Buffalo NY, 14203. The company's listed phone number is (716) 427-2950 and its investor relations email address is [email protected] The official website for Athenex is www.athenex.com.